Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arsenic trioxide, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression. for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl), in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium chloride dihydrate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - parental administration of calcium is indicated in the treatment of hypocalcaemia where rapid increase in plasma calcium is required, such as in hypocalcaemic tetany and tetany due to parathyroid deficiency. intravenous calcium is also indicated to antagonise the cardiotoxicity of hyperkalaemia.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - diagnostic: intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or opthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in the diagnosis and management of macular and vascular (including diabetic) diseases.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 0.2 g/ml - suspension - excipient ingredients: propylene glycol; glycerol; sucrose; citric acid; purified water; sodium hydroxide - for the treatment of poisoning and drug overdosage by oral ingestion.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - aid to the stereotactic or ultrasonic localising of small lesions of the breast for later surgical excision.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - naproxen, quantity: 25 mg/ml - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (crystallising); aluminium magnesium silicate; purified water; sucrose; sodium chloride; fumaric acid; methyl hydroxybenzoate; sunset yellow fcf; sodium hydroxide; flavour - treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, for the symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetylcysteine, quantity: 6 g - injection - excipient ingredients: sodium hydroxide; water for injections - as an antidote for paracetamol poisoning: acetadote injection is indicated in the treatment of paracetamol overdose to protect against hepatoxicity.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.